Insider Buying: Marker Therapeutics, Inc. (NASDAQ:MRKR) Major Shareholder Buys 554,250 Shares of Stock

Marker Therapeutics, Inc. (NASDAQ:MRKR) major shareholder Enterprise Associates 16 New purchased 554,250 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the transaction, the insider now directly owns 1,625,678 shares in the company, valued at $5,202,169.60. This trade represents a 51.73 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Marker Therapeutics Trading Down 10.0 %

Marker Therapeutics stock traded down $0.38 during midday trading on Monday, reaching $3.42. The stock had a trading volume of 59,346 shares, compared to its average volume of 31,081. Marker Therapeutics, Inc. has a twelve month low of $2.44 and a twelve month high of $6.16. The firm’s fifty day simple moving average is $3.71 and its two-hundred day simple moving average is $3.84.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH upped their price objective on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a research note on Monday, October 21st.

Institutional Trading of Marker Therapeutics

A hedge fund recently raised its stake in Marker Therapeutics stock. Wedbush Securities Inc. raised its holdings in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,500 shares of the company’s stock after acquiring an additional 24,000 shares during the quarter. Wedbush Securities Inc. owned approximately 0.78% of Marker Therapeutics worth $377,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.